News|Articles|November 19, 2026

Induction Chemoimmunotherapy and ctDNA Point Beyond PACIFIC in Unresectable Stage III NSCLC

Author(s)OncLive Staff
Fact checked by: Chris Ryan
Listen
0:00 / 0:00

Key Takeaways

  • Multiple phase 3 trials are interrogating novel consolidation and resequencing, including durvalumab plus KRAS G12C inhibitors and head-to-head comparisons of PD-1/VEGF bispecific antibodies vs durvalumab.
  • Radiotherapy paradigms are being tested with SBRT to the primary tumor before mediastinal chemoradiation and with proton vs photon chemoradiotherapy, potentially impacting local control and toxicity.
SHOW MORE

Consolidation durvalumab (Imfinzi) after concurrent chemoradiotherapy, a regimen established in the phase 3 PACIFIC trial (NCT02125461), remains the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC), but a wave of ongoing trials is testing whether that paradigm can be improved.1,2

“There are at least 8 phase 3 trials, so several opportunities to change standards of care,” Narek Shaverdian, MD, said during a presentation at the 21st Annual New York Lung Cancers Symposium.

Shaverdian, director of thoracic radiation oncology at Memorial Sloan Kettering Cancer Center in New York, New York, reviewed the trial landscape and circulating tumor DNA (ctDNA)–guided consolidation before focusing on the role of induction therapy in unresectable disease.

Key Takeaways From a New York Lung: Emerging Strategies in Locally Advanced NSCLC

  • Phase 3 trials are testing novel consolidation, radiotherapy, and resequencing strategies that could change the post-PACIFIC standard of care in unresectable stage III NSCLC.
  • The phase 2 ADAPT-C and IDEATION trials are using ctDNA to escalate or de-escalate consolidation therapy after chemoradiotherapy.
  • In the phase 2 MDT-BRIDGE trial, 92% of patients received definitive therapy after induction durvalumab plus chemotherapy, and those who went on to chemoradiotherapy had a 12-month PFS rate of 85%.

Which strategies could reshape care after PACIFIC?

Shaverdian opened with an overview of trials spanning novel consolidation, novel radiotherapy, and resequenced approaches. For patients with KRAS G12C–mutated disease, the phase 3 SUNRAY-02 (NCT06890598) and KANDLELIT-015 (NCT07554339) trials are adding olomorasib or calderasib (MK-1084), respectively, to durvalumab, and PD-1/VEGF bispecific antibodies are being compared with durvalumab in phase 3 testing.1

Radiotherapy questions are being addressed by the phase 3 NRG-LU008 trial (NCT05624996) with the evaluation of primary tumor stereotactic body radiation therapy before concurrent mediastinal chemoradiation, and the phase 3 NRG/RTOG 1308 trial (NCT01993810) is examining proton vs photon chemoradiotherapy, which could report results within the next year, Shaverdian noted. The phase 2 NEOLA trial (NCT06194448) is testing induction osimertinib (Tagrisso) before chemoradiotherapy in EGFR-mutated disease.

How is ctDNA being used to guide consolidation?

Two trials are using ctDNA molecular residual disease (MRD) to tailor consolidation in opposite directions. The phase 2 ADAPT-C trial (NCT04585490) from Stanford University is an escalation study asking whether treating molecular relapse can prevent clinical relapse.3 Patients who are 1 to 8 months into consolidation durvalumab after definitive chemoradiotherapy undergo ctDNA MRD testing, and those who are MRD positive receive 4 cycles of durvalumab plus tremelimumab (Imjudo) and a platinum doublet, with the goal of clearing ctDNA before completing 12 months of durvalumab, Shaverdian said,

The phase 2 IDEATION trial (NCT07759492) in France is taking the opposite approach, asking whether patients with negative ctDNA after chemoradiotherapy can omit durvalumab.4 Patients are randomly assigned 2:1 to a ctDNA-guided arm, in which only MRD-positive patients receive durvalumab, or a control arm; the primary end point is 12-month progression-free survival (PFS) in the ctDNA-guided arm.

Is induction therapy helpful or harmful in unresected NSCLC?

Shaverdian noted that prior studies of induction chemotherapy before chemoradiotherapy were negative, with no improvement in overall survival or PFS and added toxicity, but modern systemic therapies may change that equation.1

“Giving your best systemic therapy first could act on occult metastatic disease and possibly improve systemic disease control,” he said. The risks include progression that precludes definitive therapy and possibly more pneumonitis.

No trial has reported induction plus a PACIFIC-like approach vs a PACIFIC-like approach alone. The phase 3 GASTO-10124 trial (NCT06734702) is randomly assigning a planned 497 patients to induction tislelizumab-jsgr (Tevimbra) plus chemotherapy followed by hypofractionated or conventional chemoradiotherapy, or to chemoradiotherapy alone, with tislelizumab consolidation in all arms and 18-month PFS as the primary end point.5

Early lessons were derived from the nonrandomized phase 2 MDT-BRIDGE trial (NCT05925530), in which patients (n = 142) with resectable (65%) or borderline resectable (35%) disease received 2 cycles of induction durvalumab plus chemotherapy before multidisciplinary reassessment. The resection rate, the primary end point, was 75%.6

Overall, 92% of patients received definitive therapy: 106 underwent resection and 25 received chemoradiotherapy. Shaverdian called that the greater takeaway, “suggesting that with this approach, we’re likely not causing harm, as most patients receive definitive therapy.” Only 3 patients had disease progression during induction.1,6

Among the 25 patients treated with chemoradiotherapy, the 12-month PFS rate was 85% (95% CI, 60%-95%); the 12-month event-free survival (EFS) rate was 93% (95% CI, 86%-97%) among the 106 patients who underwent resection.6

“There appears to be some added toxicity during chemoradiation,” Shaverdian said. “Specifically, 8% of patients developed pneumonitis during chemoradiation, and that’s generally not something we expect in the absence of induction.”

The events were mainly low grade, and no grade 3/4 pneumonitis or immune-mediated adverse effects (AEs) occurred during chemoradiotherapy or consolidation.6

Could response to induction personalize radiotherapy?

Induction also raises new questions for radiation planning. Under the current standard, the primary tumor is treated to its post-induction extent, whereas nodal regions cover pretreatment involvement, with standard expansions and uniform dosing.1 Shaverdian presented a patient whose nodal disease had a complete metabolic and radiographic response to induction.

“[However], with our current standard of care, we would treat this as if there was bulky residual disease, and this raises some key questions,” he said, highlighting whether elective expansions can be reduced, whether dose can be adapted to response, and whether ctDNA could inform those choices.

MDT-BRIDGE offered early signals, with most evaluable patients (99%) being ctDNA positive at baseline, and 37% cleared ctDNA after induction.7 With clearance, the 12-month EFS rate was 100% after surgery (n = 28) vs 88.9% with detectable ctDNA (n = 40), and the 12-month PFS rate was 100% after chemoradiotherapy (n = 4) vs 77.5% with detectable ctDNA (n = 16).

Shaverdian cautioned that the numbers were “very small,” especially with the chemoradiotherapy approach.

“However, [these data] suggest that, potentially, we could use molecular data in addition to imaging data to guide some of our local therapy decision-making,” he explained.

What comes next for induction-based strategies?

Shaverdian closed with the recently IRB-approved phase 2 INSPIRE trial at Memorial Sloan Kettering, which he leads with Jamie Chaft, MD.1 The study enrolls patients with stage IIB (N2) to III NSCLC and a PD-L1 tumor proportion score below 50%, a group with a greater than 50% chance of distant relapse. Patients will receive 2 cycles of the PD-1/VEGF bispecific ivonescimab plus chemotherapy, then chemoradiotherapy to 60 Gy adapted to the post-induction disease volume without elective expansions, then ivonescimab consolidation. Nodal areas with a complete response receive 44 Gy, which Shaverdian said is more in line with postoperative dosing for microscopic disease. The primary end point is 12-month PFS.

“The goal is that this combined approach maintains safety and improves outcomes in these higher-risk patients,” he concluded.

References

  1. Shaverdian N. Looking beyond PACIFIC: emerging strategies in locally advanced NSCLC. Presented at: 21st Annual New York Lung Cancers Symposium; November 14, 2026; New York, NY.
  2. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. doi:10.1056/NEJMoa1709937
  3. Adaptive ctDNA-based personalization of treatment during consolidation therapy in NSCLC. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT04585490
  4. ctDNA-guided consolidation immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer (IDEATION). Updated August 12, 2026. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT07759492
  5. Neoadjuvant immunotherapy plus chemotherapy followed by concurrent chemoradiotherapy and consolidative immunotherapy for locally advanced non-small cell lung cancer (GASTO-10124). ClinicalTrials.gov. Updated July 24, 2025. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT06734702
  6. Reck M, Nadal E, Gay CM, et al. Neoadjuvant durvalumab + chemotherapy for resectable/borderline resectable stage IIB-IIIB NSCLC: MDT-BRIDGE primary analysis. Presented at: IASLC 2026 World Conference on Lung Cancer; September 12-15, 2026; Seoul, South Korea. Abstract OA04.02.
  7. Spicer J, Gale D, Reck M, et al. ctDNA clearance during neoadjuvant treatment and its association with outcomes in patients with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA62.

Related to this article